elafibranor

Gilead, Ipsen build the case for their PBC drugs at EASL
Pharmaphorum
Wed, 06/5/24 - 11:06 am
Gilead Sciences
Ipsen
primary biliary cholangitis
seladelpar
EASL
elafibranor
Ipsen/Genfit eye June FDA verdict for liver drug elafibranor
Pharmaphorum
Thu, 12/7/23 - 11:01 am
Genfit
Ipsen
elafibranor
primary biliary cholangitis
FDA
priority review
Ipsen, eyeing approval, reveals mixed liver disease data on challenger to Intercept and CymaBay
Fierce Biotech
Tue, 11/14/23 - 09:20 am
Ipsen
Genfit
elafibranor
liver disease
Intercept Pharma
CymaBay Therapeutics
Ipsen and Genfit to file for EMA and FDA approval for elafibranor
Clinical Trials Arena
Fri, 06/30/23 - 10:12 am
Ipsen
Genfit
EMA
FDA
elafibranor
liver disease
primary biliary cholangitis
Genfit abandons late-stage trial of NASH drug elafibranor
Pharmaforum
Thu, 07/23/20 - 10:39 am
Genfit
elafibranor
NASH
clinical trials
Biotech Genfit warns costs of failed NASH trial will drag deep into 2020
Fierce Biotech
Tue, 05/19/20 - 10:29 am
Genfit
NASH
clinical trials
elafibranor
Genfit Contender in Heated NASH Drug Race Fails in Phase 3 Study
Xconomy
Mon, 05/11/20 - 11:50 pm
Genfit
clinical trials
NASH
elafibranor
The crucial data readouts coming soon for small biotechs
EP Vantage
Thu, 04/23/20 - 12:37 pm
clinical trials
Akebia
Blueprint Medicines
Genfit
TG Therapeutics
vadadustat
Ayvakit
elafibranor
COVID-19 not expected to 'significantly delay' Genfit's phase 3 NASH readout
Fierce Biotech
Tue, 03/31/20 - 11:04 am
Genfit
NASH
clinical trials
COVID-19
elafibranor
Genfit's NASH key phase 3 data delayed
Fierce Biotech
Fri, 02/21/20 - 10:32 am
Genfit
NASH
clinical trials
elafibranor
As NASH shifts again, the focus remains on Genfit’s big readout
EP Vantage
Wed, 12/18/19 - 10:53 am
NASH
Genfit
elafibranor
Pfizer
Boehringer Ingelheim
Gilead Sciences
Poxel
Takeda
Intercept Pharma
Genfit’s liver disease Hail Mary approaches
EP Vantage
Thu, 09/19/19 - 08:10 pm
Genfit
NASH
elafibranor
GenFit Moves Lead Candidate into Another Phase III Trial with Breakthrough Therapy
BioSpace
Wed, 04/24/19 - 11:58 am
Genfit
breakthrough therapy
FDA
primary biliary cholangitis
elafibranor
Genfit bags FDA breakthrough tag on route to phase 3 in PBC
Fierce Biotech
Thu, 04/18/19 - 10:21 am
Genfit
FDA
primary biliary cholangitis
elafibranor
clinical trials
The 20 Hottest Pipeline Drugs to Watch in 2019
BioSpace
Sun, 01/6/19 - 02:09 pm
VX-659 + tezacaftor + ivacaftor
semaglutide
JCAR017
ARGX-113
aducanumab
elafibranor
NKTR-214
DS-8201
GSK2857916
ozanimod
SGT-001
valoctocogene roxaparvovec
voxelotor
While we wait for NASH data, Genfit reports positive elafibranor data in PBC patients
Endpoints
Thu, 12/6/18 - 10:02 am
Genfit
NASH
Gilead Sciences
Intercept Pharma
clinical trials
elafibranor
GENFIT Receives Positive Safety Review for NASH Candidate Elafibranor
CP Wire
Mon, 04/23/18 - 10:35 pm
Genfit
NASH
elafibranor
Genfit launches a PhIII study for NASH drug
Fierce Biotech
Tue, 11/17/15 - 09:09 am
Genmit
NASH
elafibranor
clinical trials